These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35573250)

  • 1. A Cell-free Expression Pipeline for the Generation and Functional Characterization of Nanobodies.
    Haueis L; Stech M; Kubick S
    Front Bioeng Biotechnol; 2022; 10():896763. PubMed ID: 35573250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanobodies as efficient drug-carriers: Progress and trends in chemotherapy.
    Panikar SS; Banu N; Haramati J; Del Toro-Arreola S; Riera Leal A; Salas P
    J Control Release; 2021 Jun; 334():389-412. PubMed ID: 33964364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of rabbit polyclonal antibody against camel recombinant nanobodies.
    Khalaf HE; Al-Bouqaee H; Hwijeh M; Abbady AQ
    Open Life Sci; 2022; 17(1):659-675. PubMed ID: 35800073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cDNA Immunization Strategy to Generate Nanobodies against Membrane Proteins in Native Conformation.
    Eden T; Menzel S; Wesolowski J; Bergmann P; Nissen M; Dubberke G; Seyfried F; Albrecht B; Haag F; Koch-Nolte F
    Front Immunol; 2017; 8():1989. PubMed ID: 29410663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanobodies: Robust miniprotein binders in biomedicine.
    Yong Joon Kim J; Sang Z; Xiang Y; Shen Z; Shi Y
    Adv Drug Deliv Rev; 2023 Apr; 195():114726. PubMed ID: 36754285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Camelid immunoglobulins and nanobody technology.
    Muyldermans S; Baral TN; Retamozzo VC; De Baetselier P; De Genst E; Kinne J; Leonhardt H; Magez S; Nguyen VK; Revets H; Rothbauer U; Stijlemans B; Tillib S; Wernery U; Wyns L; Hassanzadeh-Ghassabeh G; Saerens D
    Vet Immunol Immunopathol; 2009 Mar; 128(1-3):178-83. PubMed ID: 19026455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
    Bannas P; Hambach J; Koch-Nolte F
    Front Immunol; 2017; 8():1603. PubMed ID: 29213270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation and optimization of camelid single-domain antibodies: Dirk Saerens' work on nanobodies.
    Saerens D
    World J Biol Chem; 2010 Jul; 1(7):235-8. PubMed ID: 21537479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering Bacillus subtilis as a Versatile and Stable Platform for Production of Nanobodies.
    Yang M; Zhu G; Korza G; Sun X; Setlow P; Li J
    Appl Environ Microbiol; 2020 Apr; 86(8):. PubMed ID: 32060024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
    Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
    Front Immunol; 2018; 9():2553. PubMed ID: 30524421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applications of nanobodies in plant science and biotechnology.
    Wang W; Yuan J; Jiang C
    Plant Mol Biol; 2021 Jan; 105(1-2):43-53. PubMed ID: 33037986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanobodies - Little helpers unravelling intracellular signaling.
    Wagner TR; Rothbauer U
    Free Radic Biol Med; 2021 Nov; 176():46-61. PubMed ID: 34536541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoreaction of a recombinant nanobody from camelid single domain antibody fragment with Acinetobacter baumannii.
    Payandeh Z; Rasooli I; Mousavi Gargari SL; Rajabi Bazl M; Ebrahimizadeh W
    Trans R Soc Trop Med Hyg; 2014 Feb; 108(2):92-8. PubMed ID: 24463583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of specific nanobodies (VHH) for CD19 immuno-targeting of human B-lymphocytes.
    Banihashemi SR; Hosseini AZ; Rahbarizadeh F; Ahmadvand D
    Iran J Basic Med Sci; 2018 May; 21(5):455-464. PubMed ID: 29922424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 30 years of nanobodies - an ongoing success story of small binders in biological research.
    Frecot DI; Froehlich T; Rothbauer U
    J Cell Sci; 2023 Nov; 136(21):. PubMed ID: 37937477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and applications of Nanobodies against human procalcitonin selected from a novel naïve Nanobody phage display library.
    Yan J; Wang P; Zhu M; Li G; Romão E; Xiong S; Wan Y
    J Nanobiotechnology; 2015 May; 13():33. PubMed ID: 25944262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Streamlined method for parallel identification of single domain antibodies to membrane receptors on whole cells.
    Rossotti M; Tabares S; Alfaya L; Leizagoyen C; Moron G; González-Sapienza G
    Biochim Biophys Acta; 2015 Jul; 1850(7):1397-404. PubMed ID: 25819371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity Risk Profile of Nanobodies.
    Ackaert C; Smiejkowska N; Xavier C; Sterckx YGJ; Denies S; Stijlemans B; Elkrim Y; Devoogdt N; Caveliers V; Lahoutte T; Muyldermans S; Breckpot K; Keyaerts M
    Front Immunol; 2021; 12():632687. PubMed ID: 33767701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy.
    Hu Y; Liu C; Muyldermans S
    Front Immunol; 2017; 8():1442. PubMed ID: 29163515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-Domain Antibodies As Versatile Affinity Reagents for Analytical and Diagnostic Applications.
    Gonzalez-Sapienza G; Rossotti MA; Tabares-da Rosa S
    Front Immunol; 2017; 8():977. PubMed ID: 28871254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.